ETF Holdings Breakdown of TGTX

News associated with TGTX

TG Therapeutics Sees Unusually Large Options Volume (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) was the recipient of some unusual options trading on Monday. Stock traders bought 8,465 call options on the stock. This represents an increase of approximately 46% compared to the average daily volume of 5,801 call options. TG Therapeutics Price Performance Shares of NASDAQ TGTX opened at $34.86 […] - 2025-05-07 05:20:52

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 4,549.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,928 shares of the biopharmaceutical company’s stock after purchasing an additional 6,779 shares during the period. NewEdge […] - 2025-05-02 08:18:53

Envestnet Asset Management Inc. Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Envestnet Asset Management Inc. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,111 shares of the biopharmaceutical company’s stock after purchasing an additional 5,135 shares during the period. Envestnet Asset Management Inc.’s […] - 2025-04-29 07:24:54

TG Therapeutics Reaches Analyst Target Price

In recent trading, shares of TG Therapeutics Inc (Symbol: TGTX) have crossed above the average analyst 12-month target price of $40.00, changing hands for $40.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on - 2025-04-25 11:00:38

481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 481,989 shares of the biopharmaceutical company’s stock, valued at approximately $14,508,000. Raymond James Financial Inc. owned about 0.31% […] - 2025-04-22 08:11:00

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Bank of Montreal Can

Bank of Montreal Can raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,016 shares of the biopharmaceutical company’s stock after acquiring an additional 1,357 shares […] - 2025-04-21 07:38:46

Legal & General Group Plc Sells 7,065 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Legal & General Group Plc reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The fund owned 391,388 shares of the biopharmaceutical company’s stock after selling 7,065 shares during the quarter. Legal & General Group Plc’s holdings in TG Therapeutics were worth $11,781,000 as of […] - 2025-04-17 09:54:47

Norges Bank Makes New $12.09 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 401,495 shares of the biopharmaceutical company’s stock, valued at approximately $12,085,000. Norges Bank owned 0.26% of TG Therapeutics at the […] - 2025-04-08 08:26:51

Vanguard Group Inc. Grows Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vanguard Group Inc. increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,596,480 shares of the biopharmaceutical company’s stock after purchasing an additional 209,190 shares during the quarter. Vanguard Group Inc. owned […] - 2025-04-02 07:47:03

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 44.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 168,575 shares of the biopharmaceutical company’s stock after selling 136,762 shares during the period. Prudential Financial Inc.’s […] - 2025-04-01 09:04:49

KLP Kapitalforvaltning AS Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

KLP Kapitalforvaltning AS bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,700 shares of the biopharmaceutical company’s stock, valued at approximately $924,000. Other large investors have also made changes to […] - 2025-04-01 08:11:08

Thrivent Financial for Lutherans Sells 1,596 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Thrivent Financial for Lutherans lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 103,168 shares of the biopharmaceutical company’s stock after selling 1,596 shares during the period. Thrivent Financial for Lutherans’ holdings in TG Therapeutics were worth $3,105,000 as of its […] - 2025-03-27 09:08:51

28,482 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Natixis Advisors LLC

Natixis Advisors LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 28,482 shares of the biopharmaceutical company’s stock, valued at approximately $857,000. Several other institutional investors also recently […] - 2025-03-27 08:30:59

Corient Private Wealth LLC Decreases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Corient Private Wealth LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 42.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,378 shares of the biopharmaceutical company’s stock after selling 35,309 shares during the period. Corient Private […] - 2025-03-26 08:00:57

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Lessened by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 15.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 7,103 shares of the biopharmaceutical company’s stock after selling 1,269 shares during the period. PNC Financial Services Group Inc.’s holdings in TG Therapeutics were […] - 2025-03-24 08:06:54

Raymond James Financial Inc. Invests $14.51 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 481,989 shares of the biopharmaceutical company’s stock, valued at approximately $14,508,000. Several other institutional investors and hedge funds have also […] - 2025-03-19 08:30:48

TG Therapeutics (NASDAQ:TGTX) Trading 5.2% Higher on Better-Than-Expected Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report)’s stock price traded up 5.2% during mid-day trading on Tuesday following a stronger than expected earnings report. The company traded as high as $36.77 and last traded at $36.22. 973,114 shares traded hands during trading, a decline of 59% from the average session volume of 2,388,404 shares. […] - 2025-03-06 07:40:06

TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. TGTX has been the topic of a number of other reports. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and […] - 2025-03-05 08:48:52

TG Therapeutics (NASDAQ:TGTX) Sees Unusually-High Trading Volume After Strong Earnings

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) saw unusually-strong trading volume on Monday after the company announced better than expected quarterly earnings. Approximately 3,051,440 shares changed hands during trading, an increase of 42% from the previous session’s volume of 2,147,864 shares.The stock last traded at $35.04 and had previously closed at $30.09. […] - 2025-03-05 07:04:51

Stock Traders Purchase High Volume of Call Options on TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) saw some unusual options trading on Monday. Stock investors purchased 13,927 call options on the stock. This is an increase of approximately 105% compared to the typical daily volume of 6,778 call options. Analyst Upgrades and Downgrades Several equities analysts recently weighed in on TGTX shares. StockNews.com […] - 2025-03-04 08:24:49

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 8.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,700 shares of the biopharmaceutical company’s stock after selling 4,200 shares during the quarter. Handelsbanken Fonder AB’s holdings […] - 2025-02-27 09:19:07

New York State Common Retirement Fund Purchases 239,881 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Common Retirement Fund grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 403.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 299,396 shares of the biopharmaceutical company’s stock after acquiring […] - 2025-02-26 09:17:04

New York State Teachers Retirement System Boosts Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Teachers Retirement System boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 43,764 shares of the biopharmaceutical company’s stock after purchasing an additional 837 shares during the period. New […] - 2025-02-24 08:19:03

Valeo Financial Advisors LLC Acquires 3,309 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Valeo Financial Advisors LLC lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 32.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,532 shares of the biopharmaceutical company’s stock after acquiring an additional 3,309 shares during the period. Valeo Financial Advisors LLC’s […] - 2025-02-18 09:01:03

Bleakley Financial Group LLC Acquires New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Bleakley Financial Group LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 8,140 shares of the biopharmaceutical company’s stock, valued at approximately $245,000. A number of other large investors also recently made changes to their positions in TGTX. NBC Securities Inc. […] - 2025-02-13 09:38:48

Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $40.67

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among […] - 2025-02-11 07:10:51

TG Therapeutics (NASDAQ:TGTX) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a sell rating in a report published on Friday. Several other research analysts have also recently weighed in on the company. TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating […] - 2025-02-03 06:18:57

TGTX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	100,339	USD 3,397,479
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	14,617	USD 494,932 -2.9%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	177,663	USD 6,015,669
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	370	USD 12,528
Total =		292,989	USD 9,920,608

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer